Multi-center trial on the early effects of silodosin on lower urinary tract symptoms associated with benign prostatic hyperplasia

Ogawa, Takehiko, Uemura, Hiroji, Sano, Futoshi, Hoshino, Kouji, Kita, Kaoru, Hayashi, Narihiko, Kagota, Masayo, Murakami, Takayuki, Makiyama, Kazuhide, Miyoshii, Yasuhide, Nakaigawa, Noboru, Yao, Masahiro, Shimura, Hidetoshi, Furuhata, Akihiko, Fujikawa, Naoya, Shioi, Koichi, Ueki, Teiichiro, Hara, Yoshinori, Saitou, Kiyoshi, Kawakami, Satoshi, Satomi, Yoshiaki, Hattori, Yusuke, Teranishi, Junichi, Kondo, Keiichi, Kishida, Takeshi, Saito, Kazuo, Noguchi, Kazumi, Fujii, Hiroshi, Yamaguchi, Toyoaki, Kinoshita, Yuzo, Nomura, Sakae, Yoshida, Minoru, Sakai, Naoki, Terao, Hideyuki, Matsumoto, Tatsuya, Umemoto, Susumu, Ogo, Yoshiharu, Kobayashi, Kazuki, Noguchi, Sumio, Asakura, Tomoyuki, Kohdaira, Teruo, Iguchi, Kozue, Izumi, Koji, Hirano, Masami, Kanno, Hitomi, Takahashi, Toshihiro, Nukui, Fumihiko, Mokuo, Yasuhiro, Muraoka, Kentaro, Osada, Yutaka, Funahashi, Makoto, Kitami, Kazuo, Sugiura, Shimpei, Ohta, Junichi, Miura, Takeshi, Ishibashi, Yoshio, Masuda, Mitsunobu, Komiya, Atsushi, Suwa, Yutaka, Hashiba, Takafumi, Mitaka, Kunihisa, Kobayashi, Masataka, Ohsaka, Kimito, Takano, Tetsuzo, Tsuchiya, Futoshi, Iwasaki, Akira, Yamashita, Yuzo, Matsuzaki, Junichi, Kubota, Yoshinobu

Bibliographic Information

Other Title

前立腺肥大症に伴う排尿障害に対するシロドシンの服用後早期効果に関する多施設共同臨床研究(SELECTIVITY) : Silodosin Early Effectiveness and Safety Multi Center Trial in Yokohama
ゼンリツセンヒダイショウニトモナウハイニョウショウガイニタイスルシロドシンノフクヨウゴソウキコウカニカンスルタシセツキョウドウリンショウケンキュウ SELECTIVITY Silodosin Early Effectiveness and Safety Multi Center Trial in Yokohama

Search this article

Abstract

Silodosin (URIEF), a new so-called 3rd generation alpha-1 blocker, is widely expected to be effective and useful for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), due to its high specificity to alpha-1A receptor. We evaluated the efficacy of Silodosin, on 187 males 50 years old or over with the diagnosis of BPH. Silodosin significantly improved the International Prostate Symptom Score (IPSS) and quality of life (QOL) score from the day after administration was started. Among 166 patients whose data were available for the analysis of efficacy of Silodosin, 77.5% showed apparent subjective improvement. Eighty three patients, who had been taking another alpha-1 blocker but without satisfactory effects, showed almost the same improvements in IPSS and QOL score after switching to Silodosin as the remaining 83 patients who had no preceding treatment with an alpha-1 blocker. The improvements were not only in voiding symptoms but also in storage symptoms. The patients, who had serious storage symptoms, responded rather well to Silodosin and showed significant improvement. Taken together, Silodosin showed a quick effect for improving subjective symptoms and QOL, and was found to be useful for the management of LUTS with BPH.

Journal

Hinyokika Kiyo

Hinyokika Kiyo 54 (12), 757-764, 2008-12

泌尿器科紀要刊行会

Keywords

Details 詳細情報について

Export